Do I need a prescription for Pindolol 5mg tablets?

Pindolol 5mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Pindolol 5mg tablets?

Pindolol 5mg tablets is the generic name. It is available under brand names including: Pindolol 5mg tablets, Pindolol 5mg tablets, Pindolol 5mg tablets, Pindolol 5mg tablets, Pindolol 5mg tablets and 3 more. (Source: NHS dm+d — Actual Medicinal Products)

Pindolol 5mg tablets

Tablet

5mg

Oral

Antihypertensive

Unlicensed beta-blocker

Beta-adrenoceptor blocking drugs

Active ingredients:

Pindolol

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 02.04

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC C07AA03

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Primary care groupBrowse groups

NHS medication clusters used to compare prescribing patterns across GP practices

Antihypertensive

Unlicensed beta-blocker

Check interactions for Pindolol

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Pindolol

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Pindolol

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Pindolol

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

8 branded products available

8 productsShow details

8 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Pindolol on the MHRA register

Visken 5mg tablets

Advanz Pharma

Discontinued

Pindolol 5mg tablets

Alliance Healthcare (Distribution) Ltd

Discontinued

Pindolol 5mg tablets

Viatris UK Healthcare Ltd

Discontinued

Pindolol 5mg tablets

A A H Pharmaceuticals Ltd

Discontinued

Pindolol 5mg tablets

Phoenix Healthcare Distribution Ltd

Discontinued

Pindolol 5mg tablets

Waymade Healthcare Plc

Discontinued

Pindolol 5mg tablets

Sigma Pharmaceuticals Plc

Discontinued

Pindolol 5mg tablets

DE Pharmaceuticals

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Daily doseShow details

WHO defined daily dose (DDD)

15 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Sotalol 50mg/5ml oral suspension

Oral suspension

50mg/5ml

Same therapeutic group

Nadolol 100mg/5ml oral suspension

Oral suspension

100mg/5ml

Same therapeutic group

Nadolol 25mg/5ml oral solution

Oral solution

25mg/5ml

Same therapeutic group

Nadolol 10mg/5ml oral solution

Oral solution

10mg/5ml

Same therapeutic group

Nadolol 10mg/5ml oral suspension

Oral suspension

10mg/5ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Pindolol

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Pindolol

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42379711000001100

dm+d ID

42379711000001100

VTM (Virtual Therapeutic Moiety)

777201006

VMP (Virtual Medicinal Product)

42379711000001100

BNF code

02040000

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

C07AA03

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

28 found

Half-life

3-4 hours

Mechanism

The beta-1 adrenoceptor is a G-protein-coupled receptor.

Food interactions

2 warnings

Human targets

5 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

87-92%

The mean oral bioavailability of pindolol is 87-92%.
[L32388]
A 5 mg oral dose reaches a C_max of 33.1 ±…

Half-life

3-4 hours

The half life of pindolol varies from 3-4 hours[L32388] but can be as high as 30 hours in patients with cirrhosis of the liver.
[L32353]

Protein binding

40%

Pindolol is 40% bound to proteins in plasma.
[L32353]
Pindolol mainly binds more strongly to alpha-1-acid glycoprotein than it does to serum albumin.
[A231049]…

Volume of distribution

2-3 L/kg

The volume of distribution of pindolol is approximately 2-3 L/kg.
[L32353][L32388]

Metabolism

30-40%

30-40% of a dose of pindolol is not metabolized.
[L32388]
The remainder is hydroxylated and subsequently undergoes glucuronidation or sulfate conjugation.
[L32388]…

Elimination

80%

80% of an oral dose is eliminated in the urine,[L32388] with 25-40% of the dose as the unchanged parent compound.
[L32353]…

Clearance

400-500 mL/min

In otherwise healthy patients, the systemic clearance of pindolol is 400-500 mL/min.
[L32388]…

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension.[L32353] Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia.[A231059] Research into pindolol's use in the treatment of hypertension began in the early 1970s.[A231064]

Pindolol was granted FDA approval on 3 September 1982.[L32348]

Properties:

solid

Avg. mass: 248.32 Da

DrugBank indication

Pindolol is indicated in the management of hypertension.
[L32353]
In Canada, it is also indicated in the prophylaxis of angina.
[L32388]

Also known as(250)

1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol

1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol

1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol

4-(2-hydroxy-3-isopropylaminopropoxy)-indole

Pindolol

Pindololum

ADRB1R

B1AR

Dosage forms(13)

Tablet (Oral)

Tablet (Oral) — 10 mg/1

Tablet (Oral) — 5 mg/1

Tablet (Oral) — 10 mg / tab

Tablet (Oral) — 15 mg / tab

Tablet (Oral) — 5 mg / tab

Tablet (Oral) — 10 mg

Tablet (Oral) — 15 mg

Molecular properties(19)

Drug interactions(2024)

Known interactions with other medications. Always consult a healthcare professional.

Duloxetine

Major

DB00476

The risk or severity of orthostatic hypotension and syncope can be increased when Pindolol is combined with Duloxetine.

Check this interaction

Levodopa

Major

DB01235

The risk or severity of hypotension and orthostatic hypotension can be increased when Pindolol is combined with Levodopa.

Check this interaction

Risperidone

Moderate

DB00734

Pindolol may increase the hypotensive activities of Risperidone.

Check this interaction

Ceritinib

Moderate

DB09063

Pindolol may increase the bradycardic activities of Ceritinib.

Check this interaction

Ivabradine

Moderate

DB09083

Pindolol may increase the bradycardic activities of Ivabradine.

Check this interaction

Ruxolitinib

Moderate

DB08877

Ruxolitinib may increase the bradycardic activities of Pindolol.

Check this interaction

Alfuzosin

Moderate

DB00346

Alfuzosin may increase the hypotensive activities of Pindolol.

Check this interaction

Amifostine

Moderate

DB01143

Pindolol may increase the hypotensive activities of Amifostine.

Check this interaction

Diazoxide

Moderate

DB01119

Diazoxide may increase the hypotensive activities of Pindolol.

Check this interaction

Methylphenidate

Moderate

DB00422

Methylphenidate may decrease the antihypertensive activities of Pindolol.

Check this interaction

Dexmethylphenidate

Moderate

DB06701

Dexmethylphenidate may decrease the antihypertensive activities of Pindolol.

Check this interaction

Obinutuzumab

Moderate

DB08935

Pindolol may increase the hypotensive activities of Obinutuzumab.

Check this interaction

Pentoxifylline

Moderate

DB00806

Pentoxifylline may increase the hypotensive activities of Pindolol.

Check this interaction

Rituximab

Moderate

DB00073

Pindolol may increase the hypotensive activities of Rituximab.

Check this interaction

Doxapram

Moderate

DB00561

Doxapram may decrease the antihypertensive activities of Pindolol.

Check this interaction

Phenmetrazine

Moderate

DB00830

Phenmetrazine may decrease the antihypertensive activities of Pindolol.

Check this interaction

Dutasteride

Moderate

DB01126

Dutasteride may decrease the antihypertensive activities of Pindolol.

Check this interaction

Finasteride

Moderate

DB01216

Finasteride may decrease the antihypertensive activities of Pindolol.

Check this interaction

Epicaptopril

Moderate

DB02032

Epicaptopril may decrease the antihypertensive activities of Pindolol.

Check this interaction

1-benzylimidazole

Moderate

DB04581

1-benzylimidazole may decrease the antihypertensive activities of Pindolol.

Check this interaction

Tyramine

Moderate

DB08841

Tyramine may decrease the antihypertensive activities of Pindolol.

Check this interaction

Atipamezole

Moderate

DB11481

Atipamezole may decrease the antihypertensive activities of Pindolol.

Check this interaction

Siponimod

Moderate

DB12371

Siponimod may decrease the antihypertensive activities of Pindolol.

Check this interaction

Idazoxan

Moderate

DB12551

Idazoxan may decrease the antihypertensive activities of Pindolol.

Check this interaction

Tramazoline

Moderate

DB13064

Tramazoline may decrease the antihypertensive activities of Pindolol.

Check this interaction

Fenozolone

Moderate

DB13341

Fenozolone may decrease the antihypertensive activities of Pindolol.

Check this interaction

Xenon

Moderate

DB13453

Xenon may decrease the antihypertensive activities of Pindolol.

Check this interaction

Buflomedil

Moderate

DB13510

Buflomedil may decrease the antihypertensive activities of Pindolol.

Check this interaction

Mefenorex

Moderate

DB13852

Mefenorex may decrease the antihypertensive activities of Pindolol.

Check this interaction

Quinoline Yellow WS

Moderate

DB14231

Quinoline Yellow WS may decrease the antihypertensive activities of Pindolol.

Check this interaction

Selpercatinib

Moderate

DB15685

Selpercatinib may decrease the antihypertensive activities of Pindolol.

Check this interaction

Naxitamab

Moderate

DB15965

Naxitamab may decrease the antihypertensive activities of Pindolol.

Check this interaction

Buprenorphine

Moderate

DB00921

Pindolol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.

Check this interaction

Doxylamine

Moderate

DB00366

Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pindolol.

Check this interaction

Dronabinol

Moderate

DB00470

Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Pindolol.

Check this interaction

Droperidol

Moderate

DB00450

Droperidol may increase the central nervous system depressant (CNS depressant) activities of Pindolol.

Check this interaction

Hydrocodone

Moderate

DB00956

Pindolol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.

Check this interaction

Hydroxyzine

Moderate

DB00557

Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pindolol.

Check this interaction

Magnesium sulfate

Moderate

DB00653

The therapeutic efficacy of Pindolol can be increased when used in combination with Magnesium sulfate.

Check this interaction

Methotrimeprazine

Moderate

DB01403

Pindolol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.

Check this interaction

Metyrosine

Moderate

DB00765

Pindolol may increase the sedative activities of Metyrosine.

Check this interaction

Minocycline

Moderate

DB01017

Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pindolol.

Check this interaction

Nabilone

Moderate

DB00486

Nabilone may increase the central nervous system depressant (CNS depressant) activities of Pindolol.

Check this interaction

Orphenadrine

Moderate

DB01173

Pindolol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.

Check this interaction

Paraldehyde

Moderate

DB09117

Pindolol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.

Check this interaction

Perampanel

Moderate

DB08883

Perampanel may increase the central nervous system depressant (CNS depressant) activities of Pindolol.

Check this interaction

Pramipexole

Moderate

DB00413

Pindolol may increase the sedative activities of Pramipexole.

Check this interaction

Ropinirole

Moderate

DB00268

Pindolol may increase the sedative activities of Ropinirole.

Check this interaction

Rotigotine

Moderate

DB05271

Pindolol may increase the sedative activities of Rotigotine.

Check this interaction

Rufinamide

Unknown severity

DB06201

The risk or severity of adverse effects can be increased when Rufinamide is combined with Pindolol.

Check this interaction

Showing 50 of 2024 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid alcohol. Alcohol may aggravate signs and symptoms of overdose.

Advice

Take with or without food. Food does not significantly affect absorption.

Toxicity & overdose

Patients experiencing an overdose may experience excessive bradycardia, cardiac failure, hypotension, and bronchospasm.
[L32353]
Initiate treatment with symptomatic and supportive measures.
[L32353]

How it works

Mechanism of action

The beta-1 adrenoceptor is a G-protein-coupled receptor.[A230948] Agonism of the beta-1 adrenoceptor allows the Gs subunit to upregulate adenylyl cyclase, converting ATP to cyclic AMP (cAMP).[A230948] Increased concentrations of cAMP activate cAMP-dependant kinase A, phosphorylating calcium channels, raising intracellular calcium, increasing calcium exchange through the sarcoplasmic reticulum, and increasing cardiac inotropy.[A230948] cAMP-dependant kinase A also phosphorylates myosin light chains, increasing smooth muscle contractility.[A230948] Increased smooth muscle contractility in the kidney releases renin.[A230948]

Pindolol is a non-selective beta blocker.[A230958] Blocking beta-1 adrenergic receptors in the heart results in decreased heart rate and blood pressure.[A230958] By blocking beta-1 receptors in the juxtaglomerular apparatus, pindolol inhibits the release of renin, which inhibits angiotensin II and aldosterone release.[A230948][A230953] Reduced angiotensin II inhibits vasoconstriction and reduced aldosterone inhibits water retention.[A230948][A230953]

Beta-2 adrenoceptors located in the kidneys and peripheral blood vessels use a similar mechanism to activate cAMP-dependant kinase A to increase smooth muscle contractility.[A230973] Blocking of the beta-2 adrenoceptor relaxes smooth muscle, leading to vasodilation.[A230973]

Pharmacodynamics

Pindolol is a nonselective beta blocker indicated in the management of hypertension[L32353] and prophylaxis of angina.[L32388] It has a short duration of action as it is given twice daily, and a wide therapeutic window as doses can range from 10-60 mg/day.[L32353] Patients should be counselled regarding the risk of cardiac failure, exacerbating ischemic heart disease with sudden withdrawal, nonallergic bronchospasm, masking hypoglycemia in diabetics, and masking hyperthyroidism.[L32353]

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

The mean oral bioavailability of pindolol is 87-92%.
[L32388]
A 5 mg oral dose reaches a C_max of 33.1 ± 5.2 ng/mL, with a T_max of 1-2 hours.
[L32388]

Half-life

The half life of pindolol varies from 3-4 hours[L32388] but can be as high as 30 hours in patients with cirrhosis of the liver.
[L32353]

Protein binding

Pindolol is 40% bound to proteins in plasma.
[L32353]
Pindolol mainly binds more strongly to alpha-1-acid glycoprotein than it does to serum albumin.
[A231049]

Volume of distribution

The volume of distribution of pindolol is approximately 2-3 L/kg.
[L32353][L32388]

Metabolism

30-40% of a dose of pindolol is not metabolized.
[L32388]
The remainder is hydroxylated and subsequently undergoes glucuronidation or sulfate conjugation.
[L32388]

Route of elimination

80% of an oral dose is eliminated in the urine,[L32388] with 25-40% of the dose as the unchanged parent compound.
[L32353]
6-9% of an intravenous dose is eliminated in the feces.
[L32353]
Overall, 60-65% of a dose is eliminated as glucuronide and sulfate metabolites.
[L32353]

Clearance

In otherwise healthy patients, the systemic clearance of pindolol is 400-500 mL/min.
[L32388]
In patients with cirrhosis, the clearance of pindolol varies from 50-300 mL/min.
[L32353]

Drug targets(5)

Proteins and enzymes this drug interacts with in the body

Beta-1 adrenergic receptor

BE0000172

ADRB1

partial agonist

Specific functionalpha-2A adrenergic receptor binding

Cellular location

Cell membrane

General function & pharmacology

Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.

Involved in the regulation of sleep/wake behaviors PMID:31473062

Beta-2 adrenergic receptor

BE0000694

ADRB2

partial agonist

Specific functionadenylate cyclase binding

Cellular location

Cell membrane

General function & pharmacology

Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine

Beta-3 adrenergic receptor

BE0001012

ADRB3

agonist

Specific functionbeta-3 adrenergic receptor binding

Cellular location

Cell membrane

General function & pharmacology

Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis

5-hydroxytryptamine receptor 1A

BE0000291

HTR1A

antagonist

Specific functionG protein-coupled serotonin receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:22957663 PMID:3138543 PMID:33762731 PMID:37935376 PMID:37935377 PMID:8138923 PMID:8393041

Also functions as a receptor for various drugs and psychoactive substances .
PMID:22957663 PMID:3138543 PMID:33762731 PMID:38552625 PMID:8138923 PMID:8393041

Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase .
PMID:22957663 PMID:3138543 PMID:33762731 PMID:8138923 PMID:8393041

HTR1A is coupled to G(i)/G(o) G alpha proteins and mediates inhibitory neurotransmission: signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores .
PMID:33762731 PMID:35610220
Beta-arrestin family members regulate signaling by mediating both receptor desensitization and resensitization processes .
PMID:18476671 PMID:20363322 PMID:20945968

Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism .
PMID:18476671 PMID:20363322 PMID:20945968

Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior .
PMID:18476671 PMID:20363322 PMID:20945968

Plays a role in the response to anxiogenic stimuli PMID:18476671 PMID:20363322 PMID:20945968

5-hydroxytryptamine receptor 1B

BE0000797

HTR1B

antagonist

Specific functionG protein-coupled serotonin receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:10452531 PMID:1315531 PMID:1328844 PMID:1348246 PMID:1351684 PMID:1559993 PMID:1565658 PMID:1610347 PMID:23519210 PMID:23519215 PMID:29925951 PMID:8218242

Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD) .
PMID:23519210 PMID:23519215 PMID:29925951

Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase .
PMID:10452531 PMID:1315531 PMID:1328844 PMID:1348246 PMID:1351684 PMID:1559993 PMID:1565658 PMID:1610347 PMID:23519210 PMID:23519215 PMID:29925951 PMID:8218242

HTR1B is coupled to G(i)/G(o) G alpha proteins and mediates inhibitory neurotransmission by inhibiting adenylate cyclase activity .
PMID:29925951 PMID:35610220
Arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways .
PMID:29925951
Regulates the release of 5-hydroxytryptamine, dopamine and acetylcholine in the brain, and thereby affects neural activity, nociceptive processing, pain perception, mood and behavior .
PMID:18476671 PMID:20945968
Besides, plays a role in vasoconstriction of cerebral arteries PMID:15853772

Metabolizing enzymes(3)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

UGT2B7UDP-glucuronosyltransferase 2B7 · UDP-glucuronosyltransferases (UGTs)

substrate

SULT6B1Sulfotransferase 6B1 · Sulfotransferase

substrate

CYP2D6Cytochrome P450 2D6

substrate

inhibitor

Transporters(1)

Proteins that transport this drug across cell membranes

Solute carrier family 22 member 2

BE0003647

SLC22A2

substrate

Specific functionacetylcholine transmembrane transporter activity

Cellular location

Basolateral cell membrane

General function & pharmacology

Electrogenic voltage-dependent transporter that mediates the transport of a variety of organic cations such as endogenous bioactive amines, cationic drugs and xenobiotics .
PMID:9260930 PMID:9687576
Functions as a Na(+)-independent, bidirectional uniporter .
PMID:21128598 PMID:9687576
Cation cellular uptake or release is driven by the electrochemical potential, i.e. membrane potential and concentration gradient .
PMID:15212162 PMID:9260930 PMID:9687576

However, may also engage electroneutral cation exchange when saturating concentrations of cation substrates are reached (By similarity). Predominantly expressed at the basolateral membrane of hepatocytes and proximal tubules and involved in the uptake and disposition of cationic compounds by hepatic and renal clearance from the blood flow .
PMID:15783073
Implicated in monoamine neurotransmitters uptake such as histamine, dopamine, adrenaline/epinephrine, noradrenaline/norepinephrine, serotonin and tyramine, thereby supporting a physiological role in the central nervous system by regulating interstitial concentrations of neurotransmitters .
PMID:16581093 PMID:17460754 PMID:9687576

Also capable of transporting dopaminergic neuromodulators cyclo(his-pro), salsolinol and N-methyl-salsolinol, thereby involved in the maintenance of dopaminergic cell integrity in the central nervous system .
PMID:17460754
Mediates the bidirectional transport of acetylcholine (ACh) at the apical membrane of ciliated cell in airway epithelium, thereby playing a role in luminal release of ACh from bronchial epithelium .
PMID:15817714
Also transports guanidine and endogenous monoamines such as vitamin B1/thiamine, creatinine and N-1-methylnicotinamide (NMN) .
PMID:12089365 PMID:15212162 PMID:17072098 PMID:24961373 PMID:9260930

Mediates the uptake and efflux of quaternary ammonium compound choline .
PMID:9260930
Mediates the bidirectional transport of polyamine agmatine and the uptake of polyamines putrescine and spermidine .
PMID:12538837 PMID:21128598
Able to transport non-amine endogenous compounds such as prostaglandin E2 (PGE2) and prostaglandin F2-alpha (PGF2-alpha) .
PMID:11907186
Also involved in the uptake of xenobiotic 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP) .
PMID:12395288 PMID:16394027
May contribute to regulate the transport of organic compounds in testis across the blood-testis-barrier (Probable)

Carriers(1)

Proteins that carry this drug through the body

Alpha-1-acid glycoprotein 2

BE0004879

ORM2

binder

Cellular location

Secreted

General function & pharmacology

Functions as a transport protein in the blood stream. Binds various hydrophobic ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability.

Appears to function in modulating the activity of the immune system during the acute-phase reaction

Biological pathways(1)

Pindolol Action Pathway

Involved compounds

ATP,Calcium,Magnesium cation,Pindolol,Potassium cation

Scientific references(7)

Alhayek S., Preuss C.V.

Beta-Adrenergic Receptors. The Beta-Adrenergic Receptors. 1991;:1-40.

doi: 10

1007/978-1-4612-0463-3_1

PMID: 30422499 DOI: 10.1007/978-1-4612-0463-3_1

Blumenfeld J.D., Sealey J.E., Mann S.J., Bragat A., Marion R., Pecker M.S., Sotelo J., August P., Pickering T.G., Laragh J.H.

Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.

American Journal Hypertens

1999 May12(5):451-9. doi: 10.1016/s0895-7061(99)00005-9

PMID: 10342782 DOI: 10.1016/s0895-7061(99)00005-9

Clark B.J., Menninger K., Bertholet A.

Pindolol--the pharmacology of a partial agonist.

British Journal of Clinical Pharmacology

198213(Suppl 2):149S-158S. doi: 10.1111/j.1365-2125.1982.tb01904.x

PMID: 7049208 DOI: 10.1111/j.1365-2125.1982.tb01904.x

Ferguson S.S., Feldman R.D.

beta-adrenoceptors as molecular targets in the treatment of hypertension.

Can Journal Cardiology

2014 May30(5 Suppl):S3-8. doi: 10.1016/j.cjca.2014.01.017. Epub 2014 Feb 12

PMID: 24685403 DOI: 10.1016/j.cjca.2014.01.017

Belpaire F.M., Bogaert M.G., Rosseneu M.

Binding of beta-adrenoceptor blocking drugs to human serum albumin, to alpha 1-acid glycoprotein and to human serum.

European Journal of Clinical Pharmacology

198222(3):253-6. doi: 10.1007/BF00545224

PMID: 6125395 DOI: 10.1007/BF00545224

Robak J., Gryglewski R.

Influence of INPEA, pindolol and propranolol on the chronotropic and metabolic responses to -adrenergic stimulation in intact rats.

Biochemical Pharmacology

1971 Oct20(10):2749-58. doi: 10.1016/0006-2952(71)90184-5

PMID: 4398866 DOI: 10.1016/0006-2952(71)90184-5

Walter I., Kusus T., Lydtin H.

Propranolol therapy in essential hypertension.

American Heart Journal

197283(5):589-595. doi: 10.1016/0002-8703(72)90397-3

PMID: 5156091 DOI: 10.1016/0002-8703(72)90397-3

ATC classification(2 codes)

ATC C07CA03

ATC C07AA03

Affected organisms(1)

Humans and other mammals

International brands(11)

Experimental properties(5)

External resources(3)

RxList PDRhealth Drugs.com

Commercial products(59)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Pindolol

DB00960

CAS number

13523-86-9

UNII (FDA)

BJ4HF6IU1D

InChI Key (molecular fingerprint)

JZQKKSLKJUAGIC-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

2144

ChEBI

8214

PubChem Compound

4828

PubChem Substance

46508362

KEGG Compound

C07445

KEGG Drug

D00513

ChemSpider

4662

BindingDB

50019443

PharmGKB

PA450966

Therapeutic Targets Database

DAP000025

IUPHAR

Guide to Pharmacology

Wikipedia

Pindolol

ChEMBL

CHEMBL500

RxCUI

8332

HUGO Gene Nomenclature Committee (HGNC)

HGNC:285

GenAtlas

ADRB1

GeneCards

ADRB1

GenBank Gene Database

J03019

GenBank Protein Database

178200

IUPHAR

Guide to Pharmacology

UniProtKB

P08588

UniProt Accession

ADRB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:286

GenAtlas

ADRB2

GeneCards

ADRB2

GenBank Gene Database

Y00106

GenBank Protein Database

29371

IUPHAR

Guide to Pharmacology

UniProtKB

P07550

UniProt Accession

ADRB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:288

GenAtlas

ADRB3

GeneCards

ADRB3

GenBank Gene Database

M29932

GenBank Protein Database

178896

IUPHAR

Guide to Pharmacology

UniProtKB

P13945

UniProt Accession

ADRB3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5286

GenAtlas

HTR1A

GeneCards

HTR1A

GenBank Gene Database

M28269

GenBank Protein Database

189928

IUPHAR

Guide to Pharmacology

UniProtKB

P08908

UniProt Accession

5HT1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5287

GenAtlas

HTR1B

GeneCards

HTR1B

GenBank Gene Database

D10995

GenBank Protein Database

219679

IUPHAR

Guide to Pharmacology

UniProtKB

P28222

UniProt Accession

5HT1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12530

GeneCards

UGT1A1

GenBank Gene Database

M57899

GenBank Protein Database

184473

Guide to Pharmacology

2990

UniProtKB

P22309

UniProt Accession

UD11_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12531

GeneCards

UGT1A10

GenBank Gene Database

U89508

GenBank Protein Database

2039362

UniProtKB

Q9HAW8

UniProt Accession

UD110_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12535

GeneCards

UGT1A3

GenBank Gene Database

M84127

GenBank Protein Database

340135

UniProtKB

P35503

UniProt Accession

UD13_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12536

GeneCards

UGT1A4

GenBank Gene Database

M57951

GenBank Protein Database

184475

UniProtKB

P22310

UniProt Accession

UD14_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12538

GeneCards

UGT1A6

UniProtKB

P19224

UniProt Accession

UD16_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12539

GeneCards

UGT1A7

UniProtKB

Q9HAW7

UniProt Accession

UD17_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12540

GeneCards

UGT1A8

GenBank Gene Database

AF030310

GenBank Protein Database

2613044

UniProtKB

Q9HAW9

UniProt Accession

UD18_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12541

GeneCards

UGT1A9

GenBank Gene Database

S55985

GenBank Protein Database

7690346

UniProtKB

O60656

UniProt Accession

UD19_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12546

GeneCards

UGT2B15

UniProtKB

P54855

UniProt Accession

UDB15_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12553

GeneCards

UGT2B4

GenBank Gene Database

Y00317

GenBank Protein Database

37589

UniProtKB

P06133

UniProt Accession

UD2B4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12554

GeneCards

UGT2B7

GenBank Gene Database

J05428

GenBank Protein Database

340080

UniProtKB

P16662

UniProt Accession

UD2B7_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11453

GenAtlas

SULT1A1

GeneCards

SULT1A1

GenBank Gene Database

L10819

GenBank Protein Database

179042

UniProtKB

P50225

UniProt Accession

ST1A1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11454

GeneCards

SULT1A2

UniProtKB

P50226

UniProt Accession

ST1A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11455

GeneCards

SULT1A3

UniProtKB

P0DMM9

UniProt Accession

ST1A3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:30004

GeneCards

SULT1A4

UniProtKB

P0DMN0

UniProt Accession

ST1A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:17845

GenAtlas

SULT1B1

GeneCards

SULT1B1

GenBank Gene Database

D89479

UniProtKB

O43704

UniProt Accession

ST1B1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11456

GeneCards

SULT1C2

UniProtKB

O00338

UniProt Accession

ST1C2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:33543

GeneCards

SULT1C3

UniProtKB

Q6IMI6

UniProt Accession

ST1C3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11457

GeneCards

SULT1C4

UniProtKB

O75897

UniProt Accession

ST1C4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11458

GenAtlas

SULT2A1

GeneCards

SULT2A1

GenBank Gene Database

L20000

GenBank Protein Database

306702

UniProtKB

Q06520

UniProt Accession

ST2A1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:14903

GeneCards

SULT4A1

UniProtKB

Q9BR01

UniProt Accession

ST4A1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:33433

GeneCards

SULT6B1

UniProtKB

Q6IMI4

UniProt Accession

ST6B1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:8498

GenAtlas

ORM1

GeneCards

ORM1

GenBank Gene Database

X02544

GenBank Protein Database

757907

UniProtKB

P02763

UniProt Accession

A1AG1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:8499

GeneCards

ORM2

GenBank Gene Database

BC015964

GenBank Protein Database

16359000

UniProtKB

P19652

UniProt Accession

A1AG2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10966

GeneCards

SLC22A2

GenBank Gene Database

X98333

GenBank Protein Database

2281942

Guide to Pharmacology

1020

UniProtKB

O15244

UniProt Accession

S22A2_HUMAN

International reference pricing

23 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $0.24/tablet

To $1.52/tablet

Apo-Pindol 5 mg Tablet

$0.24/tablet

Gen-Pindolol 5 mg Tablet

$0.24/tablet

Novo-Pindol 5 mg Tablet

$0.24/tablet

Nu-Pindol 5 mg Tablet

$0.24/tablet

Pms-Pindolol 5 mg Tablet

$0.24/tablet

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 27 days ago(8 Mar 2026)

Back to medicines

Pindolol 5mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
11

Chemical identifiers

Pindolol

Additional database identifiers

International reference pricing

DrugBank citations

Pindolol 5mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science11

Chemical identifiers

Pindolol

Additional database identifiers

International reference pricing

DrugBank citations

Deep science
11